GlassScriptPhysician profile
Sarah Khan
NPI 1093794448
$4,909.05
in general payments reported to CMS, 2019-2025
39 companies · $1,917 in 2025
The $1,917 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $161 · 2021: $196 · 2022: $171 · 2023: $611 · 2024: $1,146 · 2025: $1,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,572 · Long Term Medical Supply Or Device Loan: $59.94 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,572.43 |
| Long Term Medical Supply Or Device Loan | $59.94 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $476.76 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $473.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $440.29 | 2023-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $410.66 | 2019-2025 | |
| Medtronic, INC. | $318.28 | 2021-2025 | Minimed 780g |
| Abbott Laboratories | $273.02 | 2019-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Xeris Pharmaceuticals, INC. | $220.98 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $206.77 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.31 | 2019-2025 | Jardiance |
| Insulet Corporation | $176.54 | 2020-2025 | Omnipod |
| Amgen INC. | $169.53 | 2019-2025 | Evenity, Prolia, Repatha |
| Alnylam Pharmaceuticals INC. | $140.00 | 2025 | |
| Abbvie INC. | $137.10 | 2019-2025 | |
| Mannkind Corporation | $132.78 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $121.26 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $112.25 | 2023-2025 | Ultomiris, Strensiq |
| Tandem Diabetes Care, INC. | $109.86 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $107.80 | 2023-2025 | Unithroid |
| Recordati_rare_diseases_inc. | $72.10 | 2024-2025 | Isturisa, Signifor Lar |
| Cequr Corporation | $54.71 | 2023-2025 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $53.76 | 2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $52.94 | 2024-2025 | |
| Amarin Pharma, INC. | $50.96 | 2019-2021 | |
| Eisai INC. | $48.07 | 2023-2024 | |
| Ibsa Pharma INC. | $43.26 | 2022-2025 | Tirosint, Tirosint, Licart |
| Astrazeneca Pharmaceuticals LP | $42.38 | 2019-2025 | |
| Medtronic Minimed, INC. | $35.79 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $35.21 | 2021-2023 | |
| Janssen Biotech, INC. | $31.21 | 2025 | |
| Althera Pharmaceuticals LLC | $27.07 | 2021-2022 | |
| Dexcom, INC. | $26.97 | 2024 | Dexcom G6 Transmitter |
| Soleno Therapeutics, INC. | $25.42 | 2025 | Vykat Xr |
| Madrigal Pharmaceuticals | $18.94 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $16.19 | 2025 | Suflave |
| Aucta Pharmaceuticals, INC. | $14.40 | 2025 | Motpoly Xr |
| Horizon Therapeutics Plc | $13.74 | 2023 | Tepezza |
| Kowa Pharmaceuticals America, INC. | $13.43 | 2023 | Seglentis |
| Janssen Pharmaceuticals, INC | $12.90 | 2019 | |
| Shire North American Group INC | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.